Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00236015 · ClinicalTrials.gov registry record · Phase 3
A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
A Phase 3 study of Anxiety Disorder, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 880
- Enrollment target
- 20
- Study locations
NCT00236015 is a Phase 3 study of Anxiety Disorder that has completed, run by Cephalon. The registered enrollment target is 880 participants, above the 381-participant average among 20 other Anxiety Disorder trials with a reported enrollment target (131% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT00236015, a Phase 3 study of Anxiety Disorder, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 880 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
Conditions Studied
Interventions
- DRUG Gabitril
Study Locations (20)
California
- Valley Clinical Research - El Centro
- Radiant Research Irvine - Irvine
- Pharmacology Research Institute - Los Alamitos
- Pharmacology Research Institute - Riverside
- Clinical Innovations, Inc. - Santa Ana
Florida
- Miami Research Associates - Miami
- Medical Research Group of Central Florida - Orange City
- Clinical Neuroscience Solutions, Inc. - Orlando
- Roskamp Institute, Clinical Trials Division - Sarasota
- Stedman Clinical Trials - Tampa
Illinois
- American Medical Research - Aurora
- Henry Lahmeyer MD & Associates - Northfield
- Midwest Center for Neurobehavioral Medicine - Oakbrook Terrace
Arizona
- Pivotol Research Centers - Mesa
- Pivotal Research Center - Peoria
Colorado
- Radiant Research - Denver
Connecticut
- University of Connecticut Health Center - Farmington
Georgia
- Emory University - Atlanta
Indiana
- Indiana University Hospital AOC - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00236015
The ClinicalTrials.gov registry entry for NCT00236015 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 880 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 381-participant average among 20 other Anxiety Disorder trials with a reported enrollment target (131% higher). The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anxiety Disorder appearing as the primary indexed condition, and to 1 intervention - of which Gabitril is the first listed.
NCT00236015 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00236015 about?
NCT00236015 is a clinical study titled "A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder". The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
What is the current status of trial NCT00236015?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 2004-11. Estimated completion is 2006-03.
What conditions does trial NCT00236015 study?
This clinical trial studies the following conditions: Anxiety Disorder.
What interventions are being tested in trial NCT00236015?
The interventions under investigation include: Gabitril (DRUG).
Who is sponsoring clinical trial NCT00236015?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00236015 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
-
Using Neurostimulation to Accelerate Change in Misophonia: a Pilot Study
RECRUITING · NA
-
Low-Intensity Focused Ultrasound and the Complex Patient
RECRUITING · NA
-
Integrated CBT to Improve Functioning in Veterans With Anxiety and Substance Use
RECRUITING · NA
-
Unified Protocol: Community Connections
RECRUITING · NA
-
Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.